FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

Leukemia

Volumn 17, Issue 10, 2003, Pages 1925-1929

  Reinhold, U ^a   Hennig, E ^a   Leiblein, S ^a   Niederwieser, D ^a   Deininger, M W N ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

BCR ABL; CML; FISH; Imatinib

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER PATIENT; CELL SELECTION; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HUMAN; INTERMETHOD COMPARISON; INTERPHASE; LEUKOCYTE; LYMPHOCYTE; MALE; NEUTROPHIL; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GENETICS; METABOLISM; METAPHASE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES; MALE; METAPHASE; MIDDLE AGED; NEUTROPHILS; PIPERAZINES; PYRIMIDINES; TRANSLOCATION, GENETIC;

EID: 0142182240     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403077     Document Type: Article

References (36)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
3. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532-538.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541-1548.
5. Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Loffler H et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. Bone Marrow Transplant 1996; 17 (Suppl. 3): S21-S24.
6. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
7. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177-2187.
8. O'Brien SG, Guilhot F. Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
9. Tbakhi A, Pettay J, Sreenan JJ, Abdel-Razeq H, Kalaycio M, Hoeltge G et al. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders. Am J Clin Pathol 1998; 109: 16-23.
10. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J et al. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res 1998; 4: 861-867.
11. Yanagi M, Shinjo K, Takeshita A, Tobita T, Yano K, Kobayashi M et al. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 1999; 13: 542-552.
12. Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G et al. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 1998; 21: 90-100.
13. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
14. Faderl S, Kantarjian HM, Talpaz M, O'Brien S. New treatment approaches for chronic myelogenous leukemia. Semin Oncol 2000; 27: 578-586.
15. Lesser ML, Dewald GW, Sison CP, Silver RT. Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet 2002; 137: 79-84.
16. Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000; 18: 1533-1538.
17. Seong D, Kantarjian HM, Albitar M, Arlinghaus R, Xu J, Talpaz M et al. Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. Ann Oncol 1999; 10: 955-959.
18. Deininger M, Lehmann T, Krahl R, Hennig E, Muller C, Niederwieser D. No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. Blood 2000; 96: 779-780.
19. Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758-4763.
20. Froncillo MC, Maffei L, Cantonetti M, Del Poeta G, Lentini R, Bruno A et al. FISH analysis for CML monitoring? Ann Hematol 1996; 73: 113-119.
21. Cox-Froncillo MC, Cantonetti M, Masi M, Lentini R, Giudiceandrea P. Maffei L et al. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. Cancer Genet Cytogenet 1995; 84: 15-18.
22. Nolte M, Werner M, Ewig M, von Wasielewski R, Wilkens L, Link H et al. Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. Leukemia Lymphoma 1996; 22: 287-294.
23. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
24. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 1395-1402.
25. Sick C, Schultheis B, Pasternak G, Kottke I, Horner S, Heissig B et al. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization. Ann Hematol 2001; 80: 9-16.
26. Garicochea B, Chase A, Lazaridou A, Goldman JM. T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. Leukemia 1994; 8: 1197-1201.
27. Eibl B, Ebner S, Duba C, Bock C, Romani N, Erdel M et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997; 20: 215-223.
28. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
29. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
30. Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579-1583.
31. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118: 771-777.
32. Wang L, Pearson K, Ferguson JE, Clark RE. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003; 120: 990-999.
33. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003; 9: 160-166.
34. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-1937.
35. Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF et al. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica 2002; 87: 979-988.
36. Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941-1949.